rhuGM-CSF

DRUG4 trials

Sponsors

Bionor Immuno AS, Aston Sci. Inc.

Conditions

Breast CancerGastric CancerHIV I InfectionHIV-1 Infection

Phase 1

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

CompletedNCT01704781

Bionor Immuno ASHIV-1 Infection

Start: 2012-09-30End: 2014-08-31Updated: 2017-03-08

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir

CompletedNCT02092116

Bionor Immuno ASHIV I Infection

Start: 2014-03-31End: 2015-12-31Updated: 2017-03-01

Phase 2

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

TerminatedNCT05163223

Aston Sci. Inc.Breast Cancer

Start: 2022-02-28End: 2024-05-31Updated: 2024-06-17

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer

Active, not recruitingNCT05771584

Aston Sci. Inc.Gastric Cancer

Start: 2023-07-04End: 2027-05-31Updated: 2026-07-22

Related Papers

Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.

2016-07-07149 citations